scholarly article | Q13442814 |
P356 | DOI | 10.1097/00005392-199701000-00098 |
P698 | PubMed publication ID | 8976281 |
P2093 | author name string | S G Jordan | |
C J Devine | |||
S M Schlossberg | |||
K D Somers | |||
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 285-290 | |
P577 | publication date | 1997-01-01 | |
P1433 | published in | Journal of Urology | Q15709979 |
P1476 | title | Proposal: trauma as the cause of the Peyronie's lesion | |
P478 | volume | 157 |
Q84949257 | A novel modification of tunical plication by plaque thinning: long-term results in treating penile curvature of Peyronie's disease |
Q26747269 | A review of the epidemiology and treatment of Peyronie's disease |
Q35738222 | Activin Receptor-Like Kinase 5 Inhibitor Attenuates Fibrosis in Fibroblasts Derived from Peyronie's Plaque |
Q90578336 | Advances in stem cell therapy for the treatment of Peyronie's disease |
Q54957145 | All about Peyronie's disease. |
Q30458422 | Are sonographic characteristics associated with progression to surgery in men with Peyronie's disease? |
Q41487802 | Clinical and epidemiological characteristics of young patients with Peyronie's disease: a retrospective study |
Q35604418 | Effect of SMAD7 gene overexpression on TGF-β1-induced profibrotic responses in fibroblasts derived from Peyronie's plaque |
Q46130680 | Effect of intralesional verapamil for treatment of Peyronie's disease: a randomized single-blind, placebo-controlled study |
Q41909374 | Effectiveness of antioxidants (propolis, blueberry, vitamin E) associated with verapamil in the medical management of Peyronie's disease: a study of 151 cases. |
Q46936674 | Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie's disease. |
Q43099012 | Efficacy and safety evaluation of pentoxifylline associated with other antioxidants in medical treatment of Peyronie's disease: a case-control study |
Q91649266 | Evolving therapies for Peyronie's disease: how can we work towards new drugs? |
Q30857029 | Experience in the use of collagenase clostridium histolyticum in the management of Peyronie's disease: current data and future prospects |
Q52991896 | Intralesional hyaluronic acid: an innovative treatment for Peyronie's disease. |
Q36395176 | Mechanisms of Disease: new insights into the cellular and molecular pathology of Peyronie's disease |
Q91649258 | Minimally invasive therapies for Peyronie's disease: the current state of the art |
Q35947455 | New discoveries in the basic science understanding of Peyronie's disease |
Q38568077 | PEYRONIE'S DISEASE: A REVIEW OF ETIOLOGY, DIAGNOSIS, AND MANAGEMENT. |
Q80297464 | Penile prosthesis implantation for end-stage erectile dysfunction after radical prostatectomy |
Q80296018 | Peyronie's Disease: A Review |
Q38901773 | Peyronie's Disease: Intralesional Therapy and Surgical Intervention |
Q42111574 | Peyronie's disease after urethral swab, an unusual complication: a case report |
Q45961053 | Peyronie's disease associated with increase in plasminogen activator inhibitor in fibrotic plaque. |
Q26768640 | Peyronie's disease: What's around the bend? |
Q40318948 | Peyronie's disease: a difficult sexual dysfunction problem. |
Q26746145 | Peyronie's disease: a literature review on epidemiology, genetics, pathophysiology, diagnosis and work-up |
Q36082087 | Peyronie's disease: the epidemiology, aetiology and clinical evaluation of deformity |
Q36757584 | Pharmacological Management of Peyronie's Disease |
Q55349667 | Prospective study to evaluate the clinical outcome of intralesional interferon-α2b in the management of Peyronie's disease. |
Q41149177 | Rationale of combination therapy with antioxidants in medical management of Peyronie's disease: results of clinical application |
Q38661272 | Recent Pathophysiological Aspects of Peyronie's Disease: Role of Free Radicals, Rationale, and Therapeutic Implications for Antioxidant Treatment-Literature Review. |
Q37325500 | Review of the surgical approaches for Peyronie's disease: corporeal plication and plaque incision with grafting |
Q46936661 | Risk factors for Peyronie's disease: a case-control study. |
Q34061326 | Role of the HLA System in the Pathogenesis of Dupuytren's Disease. |
Q54090838 | Silencing Histone Deacetylase 7 Alleviates Transforming Growth Factor-β1-Induced Profibrotic Responses in Fibroblasts Derived from Peyronie's Plaque. |
Q50050957 | Sonographic patterns of Peyronie's disease in patients with absence of palpable plaques |
Q38908920 | Structured Self-Rated Response to Iontophoresis with Verapamil and Dexamethasone in Peyronie's Disease. |
Q35914222 | Surgical alternatives for treating Peyronie's disease |
Q38794101 | Surgical treatment of Peyronie's disease with small intestinal submucosa graft patch. |
Q36651563 | The Genetic Basis of Peyronie's Disease: A Review. |
Q35933254 | The Prevalence of Peyronie's Disease in the United States: A Population-Based Study |
Q41830691 | The Therapeutic Effects of Intracavernosal Plaque Excision in Peyronie's Disease: A None Grafting or Tunical Excising Procedure |
Q46508636 | The effectiveness of transdermal electromotive administration with verapamil and dexamethasone in the treatment of Peyronie's disease. |
Q47162651 | The histopathological effects of intracavernosal mitomycin-C injection in a rat Peyronie's disease model |
Q42576277 | The pathophysiology of Peyronie's disease: beyond the Smith's space |
Q42180966 | The role of intrinsic pathway in apoptosis activation and progression in Peyronie's disease |
Q35116422 | The transcriptional signatures of cells from the human Peyronie's disease plaque and the ability of these cells to generate a plaque in a rat model suggest potential therapeutic targets |
Q37704966 | Treatment of Peyronie's disease with PDE5 inhibitors: an antifibrotic strategy |
Q30459971 | US Imaging in Peyronie's Disease |
Q37500114 | Urologists' Perceptions and Practice Patterns in Peyronie's Disease: A Korean Nationwide Survey Including Patient Satisfaction |
Search more.